Diabetes

A pill to shed fat?

December 8, 2014


Harvard researchers have created a system using human stem cells to screen for compounds that have the potential to turn white, or “bad,” fat cells into brown, or “good,” fat cells. Pictured are human pluripotent stem cell-derived fat cells. (Photo Credit Tim Ahfeldt/...

Read more about A pill to shed fat?

J&J’s Janssen Pharmaceuticals and Evotec form strategic diabetes alliance based on HSCI discoveries

July 11, 2012

A portfolio of small molecules and biologics has been licensed by Harvard University and the Howard Hughes Medical Institute from the laboratory of Harvard Stem Cell Institute Co-Director Doug Melton, co-chair of Harvard’s Department of Stem Cell and Regenerative Biology, to the German biotech firm Evotec and international giant Janssen Pharmaceuticals, a Johnson & Johnson company, as the central focus of a new program to pursue treatments and cures for diabetes.

“Our collaboration with Doug Melton’s laboratory has been extremely successful on multiple levels,” said Evotec...

Read more about J&J’s Janssen Pharmaceuticals and Evotec form strategic diabetes alliance based on HSCI discoveries

HSCI co-director Douglas Melton and Evotec collaborate on diabetes

November 6, 2013

Harvard Stem Cell Institute (HSCI) Co-director Douglas Melton, PhD, and Evotec AG have entered into their second research collaboration to find biological pathways and signals that could be therapeutically relevant to diabetic patients.

The objective of this new collaboration, dubbed “TargetEEM” (Target Enteroendocrine Mechanisms), is to screen disease-relevant animal models for novel pathways and targets that have the potential to repair mechanisms involved in insulin resistance and abnormal...

Read more about HSCI co-director Douglas Melton and Evotec collaborate on diabetes

Pages